Supplemental Table 2.
The clinical data of 69 ruptured HCC patients who survived >30 days with different definitive treatments
| Variables | Conservative treatment (n=19) | TAE/TACE or local ablation (n=40) | Staged hepatectomy (n=10) | P |
|---|---|---|---|---|
| Gender (male/female) | 18/1 | 36/4 | 7/3 | 0.18 |
| Age (years), mean±SD | 52.3±13.2 | 55.4±12.9 | 60.5±6.6 | 0.25 |
| HBsAg (positive/negative) | 16/3 | 30/10 | 9/1 | 0.53 |
| Shock on admission (yes/no) | 4/15 | 7/33 | 2/8 | 0.91 |
| Liver cirrhosis (yes/no) | 13/6 | 23/17 | 9/1 | 0.16 |
| Ruptured tumor location (RL/LL) | 10/9 | 30/10 | 7/3 | 0.22 |
| Tumor number (single/multiple) | 5/14 | 24/16 | 8/2 | 0.012 |
| Tumor size (cm), mean±SD | 9.1±3.8 | 9.1±3.1 | 7.6±2.5 | 0.41 |
| Modified LCSGJ stage (II/III/IV) | 3/9/7 | 25/11/4 | 8/2/0 | 0.001 |
| AFP (<400/≥400ng/mL) | 7/12 | 21/19 | 5/5 | 0.53 |
| Hemoglobin (g/L), mean±SD | 108.1±21.4 | 113.4±19.5 | 112.8±16.3 | 0.52 |
| ALT (U/L), mean±SD | 72.1±39.6 | 64.9±111.7 | 61.0±28.0 | 0.94 |
| Child-Pugh class (A/B/C) | 10/8/1 | 27/10/3 | 6/4/0 | 0.65 |
| Initial treatment (Conservative treatment / Surgical hemostasis/ TAE) | 3/4/12 | 4/6/30 | 0/2/8 | 0.71 |
HCC, hepatocellular carcinoma; TAE, transarterial embolization; TACE, transarterial chemoembolization; HBsAg, hepatitis B surface antigen; RL, right lobe; LL, left lobe; LCSGJ, the Liver Cancer Study Group of Japan; AFP, alpha-fetoprotein; ALT, alanine aminotransferase.